tirzepatide injection new windsor B6 Vial | Weight Loss Treatment Tirzepatide Weight Loss in Orchard

By activating GIP receptors, tirzepatide may enhance insulin secretion in a glucose-dependent manner, meaning it stimulates insulin release primarily when blood glucose levels are elevated, potentially reducing the risk of hypoglycemia

A subsequent multicenter Phase 2 trial in participants with overweight or obesity reported approximately 15.6% mean body weight reduction at 32 weeks with cagrilintide 2.4 mg plus semaglutide 2.4 mg, compared to roughly 5.1% with placebo and lower percentages with either monotherapy

Petrov PD, Yoncheva K, Gancheva V, Konstantinov S, Trzebicka B

Clinical practice reports suggest sequential use may offer intermediate benefits, but monotherapy with semaglutide often delivers superior sustained results

Semaglutide has emerged as a potential therapeutic agent for NAFLD/NASH, given its weight-reducing properties and ability to improve insulin sensitivity

How is this different from injectable semaglutide